Neither dabigatran nor rivaroxaban was linked to increased GI bleeding compared with warfarin

被引：3
|
作者：
Koretz, Ronald L. [1 ]
机构：
[1] Olive View UCLA Med Ctr, Sylmar, CA 91342 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2015年 / 163卷 / 06期
关键词：
ORAL ANTICOAGULANTS; METAANALYSIS;
D O I：
10.7326/ACPJC-2015-163-6-013
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study
    Abraham, Neena S.
    Singh, Sonal
    Alexander, G. Caleb
    Heien, Herbert
    Haas, Lindsey R.
    Crown, William
    Shah, Nilay D.
    BMJ-BRITISH MEDICAL JOURNAL, 2015, 350
  • [22] Low risk of fatal GI bleeds with rivaroxaban, despite more bleeding than with warfarin
    Lyon, Sue
    BRITISH JOURNAL OF HOSPITAL MEDICINE, 2012, 73 (12) : 670 - 670
  • [23] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Wang, Ye
    Xie, Feng
    Kong, Ming Chai
    Lee, Lai Heng
    Ng, Heng Joo
    Ko, Yu
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (06) : 575 - 585
  • [24] Our 5 Year Experience with the Risk of Gastrointestinal Bleeding in Dabigatran Compared to Warfarin
    Jiang, Chunsu
    Sherid, Muhammed
    Sayed, Amer
    Lee, Jai Eun
    Bhagatwala, Jigar
    Patel, Harsh
    Oh, Sun Jung
    Sridhar, Subbaramiah
    Sifuentes, Humberto
    GASTROINTESTINAL ENDOSCOPY, 2016, 83 (05) : AB280 - AB281
  • [25] Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation
    Ye Wang
    Feng Xie
    Ming Chai Kong
    Lai Heng Lee
    Heng Joo Ng
    Yu Ko
    Cardiovascular Drugs and Therapy, 2014, 28 : 575 - 585
  • [26] Major Bleeding Risk During Anticoagulation with Warfarin, Dabigatran, Apixaban, or Rivaroxaban in Patients with Nonvalvular Atrial Fibrillation
    Adeboyeje, Gboyega
    Sylwestrzak, Gosia
    Barron, John J.
    White, Jeff
    Rosenberg, Alan
    Abarca, Jacob
    Crawford, Geoffrey
    Redberg, Rita
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (09): : 968 - 978
  • [27] Bleeding risk with dabigatran, rivaroxaban, warfarin, and antiplatelet agent in Asians with non-valvular atrial fibrillation
    Chan, Yi-Hsin
    Yeh, Yung-Hsin
    Tu, Hui-Tzu
    Kuo, Chi-Tai
    Chang, Shang-Hung
    Wu, Lung-Sheng
    Lee, Hsin-Fu
    See, Lai-Chu
    ONCOTARGET, 2017, 8 (58) : 98898 - 98917
  • [28] In nonvalvular AF, DOAC-related risk for GI bleeding was lower with apixaban than dabigatran or rivaroxaban
    Koretz, Ronald L.
    ANNALS OF INTERNAL MEDICINE, 2017, 167 (04) : JC21 - JC21
  • [29] Bleeding Events Among New Starters and Switchers to Dabigatran Compared with Warfarin in Atrial Fibrillation
    Larsen, Torben Bjerregaard
    Gorst-Rasmussen, Anders
    Rasmussen, Lars Hvilsted
    Skjoth, Flemming
    Rosenzweig, Mary
    Lip, Gregory Y. H.
    AMERICAN JOURNAL OF MEDICINE, 2014, 127 (07): : 650 - +
  • [30] THE COST-EFFECTIVENESS OF DABIGATRAN ETEXILATE COMPARED WITH WARFARIN AND RIVAROXABAN IN THE TREATMENT OF ACUTE PULMONARY EMBOLISM IN THE UK
    Jugrin, A., V
    Ustyugova, A., V
    Urbich, M.
    Lamotte, M.
    Sunderland, T. J.
    VALUE IN HEALTH, 2014, 17 (07) : A489 - A489
12345